Fair Value Measurements (Financial Liabilities Measured At Fair Value On Recurring Basis Using Significant Unobservable Inputs) (Details) - Acquisition-related contingent consideration - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning of period	$ 135,796	$ 189,082	$ 143,502	$ 46,005
Amounts acquired	146,866	47,900	146,866	214,435
Amounts settled	(8,121)	(13,094)	(30,242)	(21,668)
Transfers (in) and/or out of Level 3	0	0	0	0
Measurement period adjustments	0	(78)	0	(11,634)
Changes in fair value recorded in earnings	11,585	(80,277)	24,790	(83,605)
Effect of currency translation	(329)	(1,210)	881	(1,210)
Fair Value Adjustments and Accretion			24,790
Payments and Other			(29,361)
End of period	285,797	$ 142,323	285,797	$ 142,323
Qualitest acquisition
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning of period			1,137
Amounts acquired			0
Fair Value Adjustments and Accretion			(1,137)
Payments and Other			0
End of period	0		0
Sumavel acquisition
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning of period			631
Amounts acquired			0
Fair Value Adjustments and Accretion			(631)
Payments and Other			0
End of period	0		0
Auxilium acquisition
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning of period			26,435
Amounts acquired			0
Fair Value Adjustments and Accretion			2,203
Payments and Other			(9,787)
End of period	18,851		18,851
Lehigh Valley Technologies, Inc. acquisitions
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning of period			97,003
Amounts acquired			0
Fair Value Adjustments and Accretion			24,686
Payments and Other			(19,389)
End of period	102,300		102,300
Voltaren Gel® acquisition
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning of period			0
Amounts acquired			142,355
Fair Value Adjustments and Accretion			(2,905)
Payments and Other			0
End of period	139,450		139,450
Other
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning of period			18,296
Amounts acquired			4,511
Fair Value Adjustments and Accretion			2,574
Payments and Other			(185)
End of period	$ 25,196		$ 25,196